Real‐life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data

OBJECTIVE: Adalimumab is a well‐established anti–tumor necrosis factor therapy for patients with ankylosing spondylitis (AS). An indigenously developed biosimilar adalimumab (bADA) (ZRC‐3197; Exemptia) is approved for prescribing in India. In this article, we present the effectiveness and tolerabili...

Descripción completa

Detalles Bibliográficos
Autores principales: Kapoor, Sanjiv, Kaushik, Viswanath V., Jain, Rahul, Rao, Vijay K.R., Gharia, Mihir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857999/
https://www.ncbi.nlm.nih.gov/pubmed/31777828
http://dx.doi.org/10.1002/acr2.11067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857999/
https://www.ncbi.nlm.nih.gov/pubmed/31777828
http://dx.doi.org/10.1002/acr2.11067

Ejemplares similares